ALK-Abello AS (ALK B):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ALK-Abello AS (ALK B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9871
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:37
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ALK-Abello AS (ALK), a subsidiary of The Lundbeck Foundation discovers, develops and commercializes immunotherapies for allergy prevention and treatment. It markets diagnostics and other services to allergy clinics. The company’s allergy immunotherapy product portfolio includes tablet-based vaccines, sublingual or drop-based vaccines, subcutaneous vaccines; and adrenaline auto-injector to treat severe allergic reactions in emergencies (anaphylaxis). ALK’s research and development pipeline products include sublingual immunotherapy tablets for addressing the ragweed, house dust mite and tree pollen allergy. The company’s products target allergies caused by grass, tree, ragweed, house dust mite, Japanese cedar, dog, venom and cat, among others. It has subsidiaries in Europe, North America, Asia-Pacific and other international markets. ALK is headquartered in Horsholm, Denmark.

ALK-Abello AS (ALK B) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ALK-Abello AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ALK-Abello AS, Medical Devices Deals, 2012 to YTD 2018 9
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ALK-Abello AS, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Alk Abello Enters into Co-Marketing Agreement with BioCSL 11
ALK-Abello Enters into Agreement with Seqirus 12
ALK-Abello Expands Partnership with Abbott Labs 13
ALK-Abello Enters Into Co-Marketing Agreement With Eddingpharm 14
ALK Enters Into Co-Promotion Agreement With MSD For Grazax 15
Licensing Agreements 16
Japan Tobacco, Torii Pharmac Enter into Licensing Agreement with ALK-Abello 16
Equity Offering 17
ALK-Abello Raises USD10.2 Million in Private Placement of AA Shares 17
ALK-Abello Raises USD101.5 Million in Private Placement of B Shares 18
Center Labs to Raise USD96 Million in Private Placement of Shares 19
Center Labs to Raise Funds through Private Placement of Shares 20
ALK-Abello AS – Key Competitors 21
ALK-Abello AS – Key Employees 22
ALK-Abello AS – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 25
Financial Announcements 25
Aug 15, 2018: ALK-Abello: Six-month interim report (Q2) 2018 25
May 04, 2018: ALK Releases Three-month interim report (Q1) 2018 26
Feb 06, 2018: ALK releases its annual report 2017 27
Nov 10, 2017: ALK-Abello: Nine-month interim report (Q3) 2017 28
Aug 16, 2017: ALK-Abello: Six-month interim report (Q2) 2017 29
Aug 16, 2017: ALK: Six-month interim report (Q2) 2017 30
May 09, 2017: ALK-Abello Announces Three-month interim report (Q1) 2017 31
Feb 07, 2017: ALK releases its annual report 2016 32
Corporate Communications 33
Nov 03, 2017: ALK appoints Soren Jelert as new Chief Financial Officer 33
Jul 31, 2017: Management change at ALK 34
Mar 03, 2017: ALK Appoints SVP of R&D for North America and International Markets 35
Jan 10, 2017: Carsten Hellmann joins ALK as new President and CEO 36
Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Tables
ALK-Abello AS, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ALK-Abello AS, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ALK-Abello AS, Deals By Therapy Area, 2012 to YTD 2018 8
ALK-Abello AS, Medical Devices Deals, 2012 to YTD 2018 9
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Alk Abello Enters into Co-Marketing Agreement with BioCSL 11
ALK-Abello Enters into Agreement with Seqirus 12
ALK-Abello Expands Partnership with Abbott Labs 13
ALK-Abello Enters Into Co-Marketing Agreement With Eddingpharm 14
ALK Enters Into Co-Promotion Agreement With MSD For Grazax 15
Japan Tobacco, Torii Pharmac Enter into Licensing Agreement with ALK-Abello 16
ALK-Abello Raises USD10.2 Million in Private Placement of AA Shares 17
ALK-Abello Raises USD101.5 Million in Private Placement of B Shares 18
Center Labs to Raise USD96 Million in Private Placement of Shares 19
Center Labs to Raise Funds through Private Placement of Shares 20
ALK-Abello AS, Key Competitors 21
ALK-Abello AS, Key Employees 22
ALK-Abello AS, Subsidiaries 23

List of Figures
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ALK-Abello AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ALK-Abello AS, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[ALK-Abello AS (ALK B):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Charles River Laboratories International Inc (CRL):医療機器:M&Aディール及び事業提携情報
    Summary Charles River Laboratories International Inc (Charles River) is a contract research organization (CRO) that provides essential products and services to accelerate the research, drug discovery and development. It offers various basic research, drug discovery and safety assessment services. Th …
  • Icon Genetics GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary Icon Genetics GmbH (Icon Genetics), a subsidiary of Denka Co Ltd, is a technology company that offers plant engineering technologies. The company develops, manufactures and markets biopharmaceutical product candidates, engineered organisms and technology platforms for plant biotechnology and …
  • Innospec Inc (IOSP):石油・ガス:M&Aディール及び事業提携情報
    Summary Innospec Inc (Innospec) is a provider of specialty chemicals. It blends, manufactures and supplies fuel additives and other specialty chemicals. Innospec’s product portfolio includes stabilizers, detergents, cold flow improvers, lubricity improvers, corrosion inhibitors, conductivity improve …
  • Xinjiang Goldwind Science & Technology Co Ltd (002202):企業の財務・戦略的SWOT分析
    Xinjiang Goldwind Science & Technology Co Ltd (002202) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s …
  • PT Kalbe Farma Tbk (KLBF):製薬・医療:M&Aディール及び事業提携情報
    Summary PT Kalbe Farma Tbk (Kalbe) provides a wide range of healthcare solutions. The company undertakes the development, manufacturing and distribution of prescription pharmaceutical products, consumer health products, nutritional products and healthcare services. Its product portfolio comprises br …
  • Suzhou Xinrong Best Medical Instrument Co Ltd-医療機器分野:企業M&A・提携分析
    Summary Suzhou Xinrong Best Medical Instrument Co Ltd (Suzhou Xinrong) is a medical device company that manufactures orthopedic medical instruments. The company prvides products such as medullary cavity plug, acetabular screws, metal ball head, stem and titanium plate anterior thoracolumbar fixed eq …
  • Japan Oil, Gas and Metals National Corp:企業の戦略的SWOT分析
    Japan Oil, Gas and Metals National Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Venture Life Group Plc (VLG):製薬・医療:M&Aディール及び事業提携情報
    Summary Venture Life Group Plc (Venture Life) is a consumer goods company that offers ageing population products. The groups product and pipeline comprise food supplements for lowering cholesterol and maintaining brain function, medical devices for improving minor aches and pains, dry eyes and itchy …
  • Kimco Realty Corp (KIM):企業の財務・戦略的SWOT分析
    Kimco Realty Corp (KIM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • LKQ Corporation:企業の戦略・SWOT・財務情報
    LKQ Corporation - Strategy, SWOT and Corporate Finance Report Summary LKQ Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Rheinmetall AG (RHM):企業の財務・戦略的SWOT分析
    Rheinmetall AG (RHM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Ardian Holding SAS:企業の戦略的SWOT分析
    Ardian Holding SAS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Banco do Nordeste SA:企業の戦略・SWOT・財務分析
    Banco do Nordeste SA - Strategy, SWOT and Corporate Finance Report Summary Banco do Nordeste SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Crownhaitai Holdings Co Ltd:企業の戦略・SWOT・財務情報
    Crownhaitai Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Crownhaitai Holdings Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Genel Energy Plc (GENL):石油・ガス:M&Aディール及び事業提携情報
    Summary Genel Energy Plc (Genel) is an independent upstream oil and gas company. It carries out acquisition, exploration, and production operations. It has interest in Taq Taq and Tawke in the Kurdistan region. The company develops the Miran and Bina Bawi gas fields in Zagros Fold belt in the Kurdis …
  • CytRx Corp (CYTR):製薬・医療:M&Aディール及び事業提携情報
    Summary CytRx Corp (CytRx) is a clinical state is a biopharmaceutical company focusing on the research and development of novel treatments for cancer. The company’s oncology based product comprises of its lead drug product candidate, aldoxorubicin (formerly INNO-206). Aldoxorubicin is a pro-drug of …
  • Bangkok Chain Hospital Public Co Ltd (BCH):企業の財務・戦略的SWOT分析
    Bangkok Chain Hospital Public Co Ltd (BCH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengt …
  • Xiangxue Pharmaceutical Co Ltd (300147):製薬・医療:M&Aディール及び事業提携情報
    Summary Xiangxue Pharmaceutical Co Ltd (XPH) is a pharmaceutical company that manufactures and distributes drugs and medicines. The company’s products include drugs, Chinese medicine pieces, medical instruments, health products and medicinal drinks, among others. It also provides healthcare suppleme …
  • NVIDIA Corp (NVDA):企業の財務・戦略的SWOT分析
    NVIDIA Corp (NVDA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • The Techint Group:企業の戦略・SWOT・財務情報
    The Techint Group - Strategy, SWOT and Corporate Finance Report Summary The Techint Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆